Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - A Sankai Gynecology Study Group (SGSG) study

Gynecologic Oncology

Volumn 99, Issue 3, 2005, Pages 591-596

  Miyagi, Yasunari ^a   Fujiwara, Keiichi ^b   Kigawa, Junzo ^c   Itamochi, Hiroaki ^c   Nagao, Shoji ^b   Aotani, Eriko ^d   Terakawa, Naoki ^c   Kohno, Ichiro ^b  

^a Japanese Red Cross Okayama Hospital   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d KITASATO INSTITUTE   (Japan)

Author keywords

Carboplatin; Intraperitoneal chemotherapy; Intravenous chemotherapy; Mathematical model; Ovarian cancer; Pharmacokinetics

Indexed keywords

CARBOPLATIN; GLUCOSE; PLATINUM;

AREA UNDER THE CURVE; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; HUMAN; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; OVARY CANCER; PERITONEAL CAVITY; PERITONEAL FLUID; PRIORITY JOURNAL; SERUM; THEORETICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BODY FLUID COMPARTMENTS; CARBOPLATIN; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; MIDDLE AGED; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL CAVITY;

EID: 28044457404     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.06.055     Document Type: Article

References (13)

1. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, and J.A. Young Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer N. Engl. J. Med. 335 1996 1950 1955
2. M. Markman, B.N. Bundy, D.S. Alberts, J.M. Fowler, D.L. Clark-Pearson, and L.F. Carson Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group J. Clin. Oncol. 19 2001 1001 1007
3. D.K. Armstrong, B.N. Bundy, R. Baergen, S.B. Lele, J. Walker, and L.J. Copeland Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172) Proc. Am. Soc. Clin. Oncol. 2002 [Abstr # 803]
4. A. du Bois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329
5. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21 2003 3194 3200
6. K. Fujiwara, N. Sakuragi, N. Yoshida, S. Suzuki, K. Maehata, and M. Nishiya First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up Gynecol. Oncol. 90 2003 637 643
7. M. Markman Intraperitoneal chemotherapy Semin. Oncol. 18 1991 248 254
8. M. Markman, P. Francis, E. Rowinsky, T. Hakes, B. Reichman, and W. Jones Intraperitoneal taxol (paclitaxel) in the management of ovarian cancer Ann. Oncol. 5 Suppl 6 1994 S55 S58
9. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J. Clin. Oncol. 7 1989 1748 1756
10. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
11. A.F. LeRoy, M.L. Wehling, H.L. Sponseller, W.S. Friauf, R.E. Solomon, and R.L. Dedrick Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry Biochem. Med. 18 1977 184 191
12. M.W. DeGregorio, B.L. Lum, W.M. Holleran, B.J. Wilbur, and B.I. Sikic Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group Cancer Chemother. Pharmacol. 18 1986 235 238
13. F. Elferink, W.J. van der Vijgh, I. Klein, W.W. Bokkel Huinink, R. Dubbelman, and J.G. McVie Pharmacokinetics of carboplatin after intraperitoneal administration Cancer Chemother. Pharmacol. 21 1988 57 60